Reuters logo
in a year
BRIEF-Abeona says announces FDA allowance of IND for phase 1/2 clinical study
May 24, 2016 / 11:31 AM / in a year

BRIEF-Abeona says announces FDA allowance of IND for phase 1/2 clinical study

May 24 (Reuters) - Abeona Therapeutics Inc

* Abeona therapeutics announces fda allowance of investigational new drug (ind) for phase 1/2 clinical study with abo-101 gene therapy for patients with sanfilippo syndrome type b (mps iiib) Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below